Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Diego Marquez-Medina

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Future Oncology (London, England)|August 29, 2015
Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancerDiego Marquez-Medina, Sanjay Popat
Lung Cancer (Amsterdam, Netherlands)|September 16, 2015
Systemic therapy for pulmonary carcinoidsDiego Marquez-Medina, Sanjay Popat
Future Oncology (London, England)|February 2, 2016
Eventual role of EGFR-tyrosine kinase inhibitors in early-stage non-small-cell lung cancerDiego Marquez-Medina, Sanjay Popat
Anticancer Research|July 31, 2014
Age does not worsen the efficacy nor tolerance to combined induction therapies in locally advanced non-small cell lung cancerDiego Marquez-Medina, Antonio Martin-Marco, Amaia Ojanguren-Garranz
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|October 12, 2012
Role of gamma-delta T-cells in cancer: another opening door to immunotherapyDiego Marquez-Medina, Joel Salla-Fortuny, Antonieta Salud-Salvia
American Journal of Clinical Pathology|May 15, 2015
Little things make big things happen: angiolymphatic invasion and tumor necrosis prognosticate the outcome of locally advanced non-small cell lung cancer treated with a prior induction therapyDiego Marquez-Medina, Antonio Martin-Marco, Sonia Gatius Caldero, et al.
Journal of Clinical Medicine|April 3, 2021
PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-AnalysisMargarita Majem, Manuel Cobo, Dolores Isla, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Future Oncology (London, England)|August 29, 2015
Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancerDiego Marquez-Medina, Sanjay Popat
Lung Cancer (Amsterdam, Netherlands)|September 16, 2015
Systemic therapy for pulmonary carcinoidsDiego Marquez-Medina, Sanjay Popat
Future Oncology (London, England)|February 2, 2016
Eventual role of EGFR-tyrosine kinase inhibitors in early-stage non-small-cell lung cancerDiego Marquez-Medina, Sanjay Popat
Anticancer Research|July 31, 2014
Age does not worsen the efficacy nor tolerance to combined induction therapies in locally advanced non-small cell lung cancerDiego Marquez-Medina, Antonio Martin-Marco, Amaia Ojanguren-Garranz
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|October 12, 2012
Role of gamma-delta T-cells in cancer: another opening door to immunotherapyDiego Marquez-Medina, Joel Salla-Fortuny, Antonieta Salud-Salvia
American Journal of Clinical Pathology|May 15, 2015
Little things make big things happen: angiolymphatic invasion and tumor necrosis prognosticate the outcome of locally advanced non-small cell lung cancer treated with a prior induction therapyDiego Marquez-Medina, Antonio Martin-Marco, Sonia Gatius Caldero, et al.
Journal of Clinical Medicine|April 3, 2021
PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-AnalysisMargarita Majem, Manuel Cobo, Dolores Isla, et al.
Pageof 1